INmune Bio Inc. Announces Expansion Of Phase II Clinical Trial For Alzheimer’s Disease In Europe; The Company Received A Cash Refund Of ~$2.8M Pursuant To An Australian Research And Development Tax Incentive
The Company received a cash refund of approximately $2.8M USD pursuant to an Australian Research and Development Tax Incentive.Boca Raton, Florida, Nov. 15, 2023 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ:INMB)